Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSB | P07858 | 8/20 | 0.43 |
| ▸ | CTSS | P25774 | 8/20 | 0.43 |
| ▸ | CTSK | P43235 | 8/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.36 |
| ▸ | USP2 | O75604 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL346101 | 0.81 | CTSB (0.52) | CTSBCTSSCTSKUSP2CYP3A4 | |
| SCHEMBL347075 | 0.70 | CTSB (0.65) | CTSBCTSSCTSKCYP2C9USP2 | |
| SCHEMBL347076 | 0.70 | CTSB (0.65) | CTSBCTSSCTSKCYP2C9USP2 | |
| SCHEMBL346539 | 0.70 | CTSS (0.47) | CTSBCTSSCTSKCYP2C9CYP3A4 | |
| SCHEMBL345226 | 0.67 | CTSB (0.64) | CTSBCTSSCTSKCYP2C9USP2 | |
| SCHEMBL345224 | 0.67 | CTSB (0.64) | CTSBCTSSCTSKCYP2C9USP2 | |
| SCHEMBL24411691 | 0.66 | LMNA (0.47) | CTSBCTSSCTSKCYP2C9USP2 | |
| SCHEMBL346446 | 0.65 | CTSS (0.67) | CTSBCTSSCTSKCYP2C9USP2 | |
| SCHEMBL8218597 | 0.63 | CTSB (0.65) | CTSBCTSSCTSKCYP2C9CYP1A2 | |
| SCHEMBL345225 | 0.63 | CTSB (0.55) | CTSBCTSSCTSKCYP2C9USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120015933-A1 | Spirocyclic nitriles as protease inhibitors | SANOFI-AVENTIS (FR) | 2012-01-19 | — | — | US | disclosed |
| US-8039480-B2 | Spirocyclic nitriles as protease inhibitors | SANOFI-AVENTIS (FR) | 2011-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015933-A1 | Spirocyclic nitriles as protease inhibitors | CTRL, SERPINB1, PREP | CTSB 31/4885CTSS 24/4885CTSK 87/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.